Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has informed Inspire Pharmaceuticals that it will require more information on the company's ophthalmic solution for the treatment of dry eye disease before the drug can be approved for marketing.
Subscribe to our email newsletter
The FDA “approvable letter” is the second such setback that the company has suffered in its attempts to gain marketing approval for the drug in the US, and will constitute a further delay in the drugs path to market as the company seeks to address the concerns raised by the agency.
In its approvable letter, the agency said the clinical studies that the company submitted in its marketing application were not consistent enough to support the efficacy of the drug.
“In the approvable letter, the FDA strongly encouraged us to meet with them to discuss how best to move forward with the application. We intend to request this meeting in the near future,” stated Dr Christy Shaffer, president and CEO of Inspire. “In addition, our Joint Development Committee with Allergan will be meeting next week to discuss strategies for the program.